CANCER DIAGNOSTICS RESEARCH

assay

Studies to Determine Cancer Aggressiveness

The blood test can also provide information that helps determine the aggressiveness of the cancer independent of imaging. The analysis is based on cancer associated cells independent of type of cancer or stage.

REFERENCES

CAMLs contains tumor markers and are ideal for companion diagnostics because they are found in all cancers and all stages of cancer.

Creatv Bio has developed more than 30 drug targets including:

  • PD-L1, PD-L2

  • HER2

  • CCR5

  • CXCR4

  • VEGFR1-2

REFERENCES

Research on Companion/Complementary Diagnostics

Many cancer drugs target specific markers on the surface of the tumor.  If the tumor does not express the marker, studies suggest that it is not expected to respond to the drug. The test to determine effective use of the therapeutic drug for a patient is called companion diagnostics.

A simple blood test can be developed for companion diagnostics for the drug, which is less riskier than tissue biopsy.

REFERENCES